{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:02:41Z","timestamp":1790715761301,"version":"4.1.0"},"reference-count":19,"publisher":"Walter de Gruyter GmbH","issue":"8","funder":[{"DOI":"10.13039\/501100003529","name":"EU","doi-asserted-by":"publisher","award":["101034427"],"award-info":[{"award-number":["101034427"]}],"id":[{"id":"10.13039\/501100003529","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>During the last decade a number of innovative treatments including gene therapies have been approved for the treatment of monogenic inherited diseases. For some neuromuscular diseases these approaches have dramatically changed the course of the disease. For others relevant challenges still remain and require disease specific approaches to overcome difficulties related to the immune response and the efficient transduction of target cells. This review provides an overview of the current development status of mutation specific\u00a0treatments for neuromuscular diseases and concludes with on outlook on future developments and perspectives.<\/jats:p>","DOI":"10.1515\/jpm-2021-0435","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T21:09:36Z","timestamp":1631221776000},"page":"1011-1015","source":"Crossref","is-referenced-by-count":6,"title":["Postnatal gene therapy for neuromuscular diseases\u00a0\u2013 opportunities and limitations"],"prefix":"10.1515","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1618-7386","authenticated-orcid":false,"given":"Janbernd","family":"Kirschner","sequence":"first","affiliation":[{"name":"Department of Neuropediatrics , Medical Faculty, University Hospital Bonn , Bonn , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"2023040100254030019_j_jpm-2021-0435_ref_001","doi-asserted-by":"crossref","unstructured":"Bulaklak, K, Gersbach, CA. The once and future gene therapy. Nat Commun 2020;11:5820. https:\/\/doi.org\/10.1038\/s41467-020-19505-2.","DOI":"10.1038\/s41467-020-19505-2"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_002","unstructured":"Kirschner, J, Cathomen, T. Gentherapien bei monogenen Erbkrankheiten: Chancen und Herausforderungen. Dtsch Arztebl Int 2020;117:878\u201385."},{"key":"2023040100254030019_j_jpm-2021-0435_ref_003","doi-asserted-by":"crossref","unstructured":"Schorling, DC, Pechmann, A, Kirschner, J. Advances in treatment of spinal muscular atrophy\u00a0\u2013 new phenotypes, new challenges, new implications for care. J Neuromuscul Dis 2020;7:1\u201313. https:\/\/doi.org\/10.3233\/jnd-190424.","DOI":"10.3233\/JND-190424"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_004","doi-asserted-by":"crossref","unstructured":"Wirth, B. Spinal muscular atrophy: in the challenge lies a solution. Trends Neurosci 2021;44:306\u201322. https:\/\/doi.org\/10.1016\/j.tins.2020.11.009.","DOI":"10.1016\/j.tins.2020.11.009"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_005","doi-asserted-by":"crossref","unstructured":"Finkel, RS, Mercuri, E, Darras, BT, Connolly, AM, Kuntz, NL, Kirschner, J, et al.. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377:1723\u201332. https:\/\/doi.org\/10.1056\/nejmoa1702752.","DOI":"10.1056\/NEJMoa1702752"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_006","doi-asserted-by":"crossref","unstructured":"Mercuri, E, Darras, BT, Chiriboga, CA, Day, JW, Campbell, C, Connolly, AM, et al.. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018;378:625\u201335. https:\/\/doi.org\/10.1056\/nejmoa1710504.","DOI":"10.1056\/NEJMoa1710504"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_007","doi-asserted-by":"crossref","unstructured":"Dhillon, S. Risdiplam: first approval. Drugs 2020;80:1853\u20138. https:\/\/doi.org\/10.1007\/s40265-020-01410-z.","DOI":"10.1007\/s40265-020-01410-z"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_008","doi-asserted-by":"crossref","unstructured":"Kirschner, J, Butoianu, N, Goemans, N, Haberlova, J, Kostera-Pruszczyk, A, Mercuri, E, et al.. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol 2020;28:38\u201343. https:\/\/doi.org\/10.1016\/j.ejpn.2020.07.001.","DOI":"10.1016\/j.ejpn.2020.07.001"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_009","doi-asserted-by":"crossref","unstructured":"De Vivo, DC, Bertini, E, Swoboda, KJ, Hwu, WL, Crawford, TO, Finkel, RS, et al.. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 2019;29:842\u201356. https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007.","DOI":"10.1016\/j.nmd.2019.09.007"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_010","doi-asserted-by":"crossref","unstructured":"Dangouloff, T, Vrscaj, E, Servais, L, Osredkar, D, Group, SNWS. Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscul Disord 2021;31:574\u201382. https:\/\/doi.org\/10.1016\/j.nmd.2021.03.007.","DOI":"10.1016\/j.nmd.2021.07.279"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_011","doi-asserted-by":"crossref","unstructured":"Vill, K, Schwartz, O, Blaschek, A, Glaser, D, Nennstiel, U, Wirth, B, et al.. Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years. Orphanet J Rare Dis 2021;16:153. https:\/\/doi.org\/10.1186\/s13023-021-01783-8.","DOI":"10.1186\/s13023-021-01783-8"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_012","doi-asserted-by":"crossref","unstructured":"Birnkrant, DJ, Bushby, K, Bann, CM, Apkon, SD, Blackwell, A, Brumbaugh, D, et al.. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 2018;17:251\u201367. https:\/\/doi.org\/10.1016\/s1474-4422(18)30024-3.","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_013","doi-asserted-by":"crossref","unstructured":"Dzierlega, K, Yokota, T. Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Gene Ther 2020;27:407\u201316. https:\/\/doi.org\/10.1038\/s41434-020-0156-6.","DOI":"10.1038\/s41434-020-0156-6"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_014","doi-asserted-by":"crossref","unstructured":"McDonald, CM, Campbell, C, Torricelli, RE, Finkel, RS, Flanigan, KM, Goemans, N, et al.. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:1489\u201398. https:\/\/doi.org\/10.1016\/S0140-6736(17)31611-2.","DOI":"10.1016\/S0140-6736(17)31611-2"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_015","doi-asserted-by":"crossref","unstructured":"Mendell, JR, Al-Zaidy, SA, Rodino-Klapac, LR, Goodspeed, K, Gray, SJ, Kay, CN, et al.. Current clinical applications of in\u00a0vivo gene therapy with AAVs. Mol Ther 2021;29:464\u201388. https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.007.","DOI":"10.1016\/j.ymthe.2020.12.007"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_016","doi-asserted-by":"crossref","unstructured":"Chemello, F, Bassel-Duby, R, Olson, EN. Correction of muscular dystrophies by CRISPR gene editing. J Clin Invest 2020;130:2766\u201376. https:\/\/doi.org\/10.1172\/jci136873.","DOI":"10.1172\/JCI136873"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_017","doi-asserted-by":"crossref","unstructured":"Graham, RJ, Muntoni, F, Hughes, I, Yum, SW, Kuntz, NL, Yang, ML, et al.. Mortality and respiratory support in X-linked myotubular myopathy: a RECENSUS retrospective analysis. Arch Dis Child 2020;105:332\u20138. https:\/\/doi.org\/10.1136\/archdischild-2019-317910.","DOI":"10.1136\/archdischild-2019-317910"},{"key":"2023040100254030019_j_jpm-2021-0435_ref_018","unstructured":"Audentes, A. Therapeutics presents new positive data from ASPIRO, the clinical trial evaluating AT132 in patients with X-linked myotubular myopathy (XLMTM). In: The 24th International annual congress of the World Muscle Society San Francisco: Business Wire; 2019. Available from: https:\/\/www.audentestx.com\/press_release\/audentes-therapeutics-presents-new-positive-data-aspiro-clinical\/."},{"key":"2023040100254030019_j_jpm-2021-0435_ref_019","doi-asserted-by":"crossref","unstructured":"Paulk, N. Gene therapy: it\u2019s time to talk about high-dose AAV 2020. Available from: https:\/\/www.genengnews.com\/topics\/genome-editing\/gene-therapy-its-time-to-talk-about-high-dose-aav\/.","DOI":"10.1089\/gen.40.09.04"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2021-0435\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2021-0435\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T15:02:36Z","timestamp":1680361356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2021-0435\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,25]]},"published-print":{"date-parts":[[2021,10,26]]}},"alternative-id":["10.1515\/jpm-2021-0435"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2021-0435","relation":{},"ISSN":["0300-5577","1619-3997"],"issn-type":[{"value":"0300-5577","type":"print"},{"value":"1619-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]}}}